past
decad
sever
notabl
virus
suddenli
emerg
obscur
anonym
becom
seriou
global
health
threat
provok
concern
regard
sustain
epidem
transmiss
immunolog
naiv
human
popul
new
threat
come
call
rapid
vaccin
develop
inde
vaccin
consid
critic
compon
diseas
prevent
emerg
viral
infect
mani
case
medic
option
limit
nonexist
infect
result
rapid
clinic
deterior
effect
therapeut
limit
classic
approach
vaccin
develop
still
amen
emerg
virus
applic
molecular
techniqu
virolog
profoundli
influenc
understand
viru
biolog
vaccin
method
base
replic
attenu
nonrepl
viru
vector
approach
becom
use
vaccin
platform
togeth
grow
understand
viral
diseas
emerg
rang
vaccin
strategi
intern
commit
underpin
develop
vaccin
intervent
new
emerg
virus
may
becom
possibl
immun
arguabl
appropri
way
prevent
infecti
diseas
control
mani
import
viral
pathogen
vaccin
perhap
one
outstand
achiev
medic
intervent
vaccineinduc
immun
establish
advanc
viru
infect
reli
primarili
adapt
immun
respons
protect
efficaci
critic
vaccin
depend
properti
antigen
recognit
activ
expans
memori
traffick
multitud
specialist
function
lymphocyt
extent
vaccineinduc
immun
success
also
determin
spread
mainten
viral
pathogen
within
popul
viral
vaccin
profound
endur
consequ
human
anim
health
worldwid
erad
smallpox
rinderpest
testament
outstand
contribut
modern
societi
nevertheless
infecti
diseas
still
pose
one
greatest
threat
public
health
past
three
decad
brought
constant
barrag
new
human
pathogen
infect
zoonot
enter
either
directli
wildlif
reservoir
indirectli
via
intermedi
domest
anim
host
hiv
avian
influenza
hendra
hev
nipah
niv
virus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
marburg
filovirus
lassa
viru
lasv
rift
valley
fever
viru
rvfv
crimeancongo
haemorrhag
fever
cchf
virus
exampl
zoonos
current
emerg
wildlif
emerg
zoonos
present
seriou
increas
threat
health
biosecur
economi
worldwid
mechan
underli
diseas
transmiss
anim
human
becom
better
understood
emerg
pathogen
wildlif
repres
greatest
threat
global
health
occur
nonuniform
pattern
local
distinct
geograph
hotspot
africa
asia
south
america
highthreat
pathogen
weight
toward
key
wildlif
speci
eg
bat
rodent
nonhuman
primat
nhp
clear
diseas
continu
place
substanti
burden
global
health
especi
dens
human
popul
pressur
environment
econom
resourc
greatest
one
billion
case
human
zoonot
diseas
estim
occur
annual
emerg
zoonos
result
enorm
econom
loss
increas
urban
intern
travel
commerc
climat
chang
increas
likelihood
emerg
zoonosi
continu
worsen
futur
zoonot
viru
spill
suscept
new
speci
often
advantag
new
host
littl
preexist
immun
enabl
attach
entri
replic
viru
recept
cell
amplifi
viru
may
evad
clearanc
host
defenc
long
enough
transmit
anoth
suscept
host
lack
herd
immun
result
rapid
dissemin
viru
lead
diseas
virul
case
infect
step
process
repres
opportun
vaccineinduc
immun
intervent
transmitt
suscept
host
remov
popul
preemptiv
develop
protect
immun
spread
infect
becom
less
like
vaccin
therefor
power
strategi
prevent
control
emerg
zoonot
infecti
diseas
develop
vaccin
emerg
infect
howev
need
contend
sever
key
challeng
associ
virus
emerg
infect
may
recent
discov
viru
result
rare
outbreak
basic
biolog
inform
correl
protect
antigen
variabl
immunodomin
unknown
may
lack
time
develop
appropri
anim
model
diseas
studi
viral
immunolog
evalu
vaccin
candid
preclin
assess
protect
efficaci
safeti
addit
mani
emerg
virus
high
case
fatal
rate
spread
easili
treat
characterist
mandat
experiment
investig
infecti
materi
carri
high
level
biosafeti
biosafeti
level
pathogen
avail
resourceheavi
laboratori
infrastructur
bottleneck
basic
research
moreov
often
standard
vaccin
approach
use
attenu
strain
inactiv
viral
vaccin
alway
feasibl
option
possibl
revers
virul
requir
largescal
cultur
product
high
contain
facil
addit
signific
hurdl
econom
cost
novel
human
vaccin
develop
rare
pathogen
unlik
provid
effect
payback
invest
major
impedi
progress
thu
basic
research
mani
emerg
pathogen
neglect
year
unpredict
size
speed
reach
ebola
viru
outbreak
west
africa
act
wakeup
call
research
pharmaceut
commun
govern
emphas
import
invest
studi
emerg
pathogen
spur
develop
request
member
state
may
world
health
organ
conven
broad
coalit
expert
develop
research
develop
r
blueprint
action
prevent
epidem
focus
sever
emerg
diseas
potenti
gener
public
health
emerg
insuffici
prevent
cur
solut
exist
r
blueprint
specifi
r
need
includ
vaccin
research
intern
govern
programm
aim
defin
r
roadmap
priorit
pathogen
catalys
fund
strategi
key
develop
success
effect
vaccin
design
antigen
deliveri
system
optim
antigen
present
induc
broad
protect
immun
respons
recent
advanc
vector
deliveri
technolog
immunolog
basic
virolog
led
deeper
understand
molecular
cellular
mechan
vaccin
stimul
arm
adapt
immun
respons
therebi
offer
novel
strategi
vaccin
discuss
current
vaccin
approach
safe
effect
vaccin
encompass
recombin
viru
technolog
nucleic
acid
vaccin
selfdissemin
vaccin
approach
advanc
recombin
virolog
viru
revers
genet
provid
key
insight
replic
pathogenesi
wide
rang
virus
notabl
facilit
develop
vector
protein
express
vaccin
date
sever
viru
famili
exploit
vector
includ
mani
vaccin
fig
basic
advantag
viral
vector
vaccin
choic
antigen
express
context
activ
heterolog
viral
infect
stimul
full
gamut
innat
immun
respons
requir
develop
adapt
humor
cellmedi
immun
import
aspect
virusvector
vaccin
emerg
virus
characterist
type
intens
immun
respons
well
safeti
consider
manufactur
techniqu
determin
predominantli
vector
pathogen
therefor
develop
test
vaccin
newli
discov
viru
significantli
shorten
use
viral
vector
platform
extens
record
safeti
efficaci
vaccin
emerg
pathogen
research
clinic
part
vesicular
stomat
viru
vsv
neg
sens
rna
viru
rhabdovirida
famili
becom
promin
replicationcompet
vaccin
vector
platform
vsv
nonpathogen
human
inher
abil
elicit
strong
cellular
humor
immun
respons
one
use
aspect
viru
vector
platform
almost
promiscu
abil
assembl
recombin
vsv
rvsv
mani
differ
type
heterolog
viral
glycoprotein
platform
design
vsv
g
protein
replac
heterolog
envelop
glycoprotein
exampl
emerg
viru
arrang
render
rvsv
replic
compet
recombin
virus
gener
highli
attenu
attenu
yellow
fever
yf
viru
via
success
round
serial
passag
led
develop
yf
vaccin
term
impact
success
vaccin
recogn
award
nobel
prize
wide
adopt
human
immun
year
base
util
vaccin
infecti
cdna
clone
viru
enabl
develop
platform
use
drive
antigen
deliveri
pathogen
interest
technolog
licenc
well
suit
similarli
relat
flavivirus
success
recombin
construct
involv
simpl
swap
prmme
gene
membran
envelop
antigen
emerg
flavivirus
japanes
enceph
dengu
west
nile
result
recombin
vaccin
effici
deliv
liveattenu
viru
context
safeti
profil
afford
nonstructur
gene
licenc
vaccin
japanes
enceph
use
technolog
develop
sanofi
pasteur
lyon
franc
replicationcompet
platform
eas
direct
manipul
viral
genom
togeth
grow
understand
biolog
led
develop
attenu
viru
vaccin
increas
safeti
immunogen
exampl
new
vaccin
candid
rvfv
develop
viral
virul
factor
delet
result
highli
attenu
immunogen
replic
viru
similar
recombin
approach
use
attenu
emerg
neglect
pathogen
mayaro
viru
mayv
swap
subgenom
promot
alphaviru
intern
ribosom
entri
site
reduc
express
mayv
structur
protein
vaccin
emerg
pathogen
research
clinic
part
arrang
make
viru
unabl
infect
mosquito
cell
replic
mammalian
cell
still
possibl
result
highli
immunogen
profil
similar
studi
infecti
clone
virus
demonstr
genomewid
deoptim
codon
usag
dramat
reduc
gene
express
use
attenu
otherwis
pathogen
virus
strategi
use
prototyp
arenaviru
lymphocyt
choriomening
viru
lcmv
studi
show
attenu
otherwis
fatal
mous
model
lcm
diseas
abil
induc
protect
immun
togeth
maintain
robust
abil
multipli
cell
cultur
live
attenu
approach
may
suitabl
similar
virus
howev
work
underpin
confid
genet
stabil
attenu
virus
critic
consider
given
use
approach
clinic
intervent
especi
consid
inher
high
error
rate
arenaviru
polymeras
sever
year
recombin
adenovirus
adopt
promis
tool
antigen
deliveri
vaccin
efficaci
delet
gene
adenovir
genom
suppli
tran
packag
cell
line
allow
replicationdefici
recombin
adenoviru
produc
novel
heterolog
antigen
gene
interest
insert
locu
earli
setback
platform
technolog
relat
preexist
antiadenoviru
vector
antibodi
human
resolv
adopt
simian
adenovirus
vaccin
vector
number
differ
replicationdefici
vaccin
vector
recent
develop
simian
adenovirus
platform
progress
work
emerg
pathogen
ebola
viru
rvfv
merscov
zika
viru
modifi
vaccinia
viru
ankara
mva
licens
thirdgener
vaccinia
type
vaccin
smallpox
serv
potent
vector
system
develop
new
candid
vaccin
rang
infecti
diseas
includ
caus
emerg
pathogen
histor
mva
develop
serial
tissu
cultur
passag
primari
chicken
cell
vaccinia
viru
strain
ankara
clinic
use
avoid
undesir
side
effect
convent
vaccinia
vaccin
adapt
growth
avian
cell
mva
replic
mammalian
host
lack
mani
viral
immun
evas
gene
featur
mva
capac
accommod
larg
gene
insert
thermost
applic
remot
region
without
establish
cold
chain
eas
inexpens
manufactur
gmp
standard
establish
regulatori
packag
develop
investig
new
drug
make
recombin
mva
platform
highli
versatil
heterolog
viral
vector
context
emerg
infect
recombin
mva
platform
shown
encourag
preclin
efficaci
ebola
zika
chikungunya
cchf
virus
addit
mva
elicit
strong
immunolog
respons
rang
orthopoxvirus
opxv
includ
variola
vaccin
base
platform
consid
provid
ad
valu
human
immun
opxv
low
cessat
smallpox
vaccin
campaign
open
gap
opxv
emerg
evidenc
recent
occurr
monkeypox
viru
west
africa
onward
cross
boarder
transmiss
rna
replicon
system
deriv
either
positiveor
negativestrand
rna
viru
genom
embodi
disabl
viru
vector
nonpathogen
unabl
revert
virul
driven
autonom
rna
replic
rna
replicon
result
highlevel
cytosol
express
recombin
heterolog
antigen
stimul
humor
cellular
arm
immun
system
replicon
vaccin
approach
close
follow
technic
develop
genet
manipul
viral
genom
rna
virus
replicon
base
positivestrand
picornavirus
first
follow
base
alphavirus
negativestrand
rna
virus
seri
differ
vaccin
replicon
system
avail
new
capabl
negativestrand
virus
open
opportun
wider
rang
emerg
virus
recent
develop
includ
construct
lasv
replicon
packag
lasvlik
particl
allow
singl
round
replic
abl
confer
protect
otherwis
lethal
challeng
lasv
guinea
pig
model
diseas
recombin
replicon
devoid
viral
glycoprotein
gene
incorpor
vlp
achiev
use
cell
line
express
glycoprotein
separ
tran
enabl
scalabl
propag
replicon
particl
way
aim
combin
safeti
replicondeliv
lasv
antigen
conveni
simpli
rapidli
produc
attenu
viru
similar
replicon
approach
use
develop
promis
repliconbas
vaccin
candid
ebola
viru
rvfv
replicon
approach
potenc
live
attenu
vaccin
inher
safer
design
ensur
singl
cycl
replic
contrast
fulli
replic
live
attenu
vaccin
viru
live
attenu
rna
viru
vaccin
incorpor
errorpron
polymeras
revers
virul
distinct
possibl
multipl
round
replic
interest
use
viruslik
particl
vlp
vaccin
candid
stem
abil
present
order
highli
antigen
structur
immun
system
time
lack
viral
genom
potenti
yield
safer
vaccin
viral
vaccin
emerg
pathogen
research
clinic
part
sequenc
revert
virul
induc
strong
b
cell
respons
absenc
adjuv
effici
crosslink
specif
receptor
b
cell
also
trigger
cellmedi
respons
basi
order
viral
selfassembl
protein
subunit
note
mani
differ
viru
famili
provid
foundat
work
vlp
differ
virus
infect
human
anim
identifi
abl
produc
vlp
structur
divers
singl
multipl
capsid
protein
lipid
envelop
although
virus
suitabl
vlp
candid
elicit
protect
respons
without
requir
multipl
booster
shoot
thu
significantli
reduc
vaccin
cost
date
vlpbase
vaccin
human
papilloma
viru
hpv
hepat
b
viru
hbv
hepat
e
viru
hev
licens
commerci
avail
worldwid
sever
vlpbase
vaccin
candid
human
diseas
clinic
develop
includ
direct
norwalk
viru
ebola
marburg
virus
hepat
c
viru
vlp
vaccin
combin
mani
immunogen
advantag
wholeviru
vaccin
safeti
advantag
recombin
subunit
vaccin
dna
vaccin
emerg
safer
altern
standard
live
inactiv
vaccin
treat
human
anim
infect
exhibit
sever
advantag
tradit
strategi
term
safeti
stabil
eas
manufactur
immunogen
offer
potenti
advantag
vaccin
emerg
virus
plasmid
express
viral
antigen
produc
rapidli
furthermor
antigen
express
vivo
induc
humor
cellmedi
immun
respons
addit
larg
quantiti
dna
produc
short
time
reduc
cost
dna
prepar
stabl
type
vaccin
desir
properti
vaccin
may
use
remot
area
furthermor
dna
vaccin
consid
safe
howev
main
limit
develop
dna
vaccin
intrins
low
immunogen
work
improv
focus
optim
deliveri
approach
use
gene
gun
electropor
target
immun
effector
cell
use
potent
adjuv
dna
vaccin
also
frequent
use
combin
vaccin
platform
heterolog
primeboost
strategi
dna
vaccin
current
licens
immun
hors
west
nile
viru
undergon
phase
clinic
trial
human
dna
vaccin
also
evalu
candid
mani
emerg
virus
includ
ebov
rvfv
dengu
viru
chikv
synthet
peptidebas
epitopevaccin
ev
make
use
short
antigenderiv
peptid
fragment
present
either
cell
b
cell
ev
offer
sever
advantag
form
vaccin
particularli
regard
safeti
eas
product
storag
distribut
without
cold
chain
issu
also
offer
opportun
vaccin
sever
pathogen
multipl
epitop
pathogen
howev
drawback
includ
poor
immunogen
restrict
approach
patient
given
tissu
type
human
leucocyt
antigen
hla
haplotyp
need
tailor
accommod
natur
variat
hla
gene
although
initi
thought
major
impedi
new
technolog
made
personalizedmedicin
approach
feasibl
recent
bioinformat
tool
develop
identifi
put
cell
epitop
map
surfac
glycoprotein
emerg
virus
lasv
nipv
hendra
vaccin
candid
still
need
experiment
test
approach
repres
interest
novel
strategi
show
promis
vaccin
could
also
address
immun
particular
target
popul
induct
immun
respons
deliveri
inactiv
pathogen
standard
success
vaccin
approach
mani
year
licenc
inactiv
vaccin
diseas
poliomyel
rabi
commerci
avail
long
histori
approach
underpin
welldefin
regulatori
framework
readili
appli
new
diseas
target
major
challeng
inactiv
viru
approach
infect
establish
therefor
full
adapt
immun
respons
gener
achiev
howev
absenc
live
pathogen
type
vaccin
safe
basic
capabl
prepar
vaccin
especi
emerg
use
might
worthwhil
stopgap
altern
longerterm
approach
develop
regard
studi
viru
inactiv
xray
radiat
simpl
cheap
altern
gamma
irradi
use
radioact
isotop
maintain
tertiari
antigen
structur
viru
particl
destroy
infect
shown
use
promis
rang
applic
includ
vaccin
b
afrough
unpublish
vaccin
play
pivot
role
host
protect
infecti
diseas
significantli
reduc
mortal
worldwid
howev
mani
vaccin
candid
emerg
diseas
fail
make
clinic
develop
perhap
surpris
given
breadth
vaccin
technolog
avail
natur
mani
diseas
question
case
point
lassa
fever
viral
haemorrhag
ill
endem
mani
part
west
africa
respons
case
seriou
diseas
approxim
death
year
sinc
discoveri
year
ago
often
headlin
commonli
export
vhf
territori
includ
unit
kingdom
receiv
disproportion
share
travellerrel
case
incid
place
substanti
burden
public
health
resourc
lasv
caus
unusu
larg
increas
case
nigeria
led
classifi
grade
public
health
emerg
howev
despit
high
burden
lassa
fever
public
attent
vaccin
far
approv
multipl
approach
develop
rang
effect
preclin
candid
made
last
three
decad
includ
attenu
vaccin
replic
compet
vaccin
nonrepl
lasv
vaccin
ration
design
live
attenu
vaccin
dna
vaccin
addit
mani
platform
shown
efficaci
anim
model
includ
nhp
preclin
data
illustr
multipl
vaccin
technolog
potenti
yield
protect
lassa
fever
vaccin
therefor
lack
clinic
vaccin
year
sinc
diseas
first
describ
must
due
factor
econom
consider
safeti
issu
perhap
connect
grow
burden
regulatori
threshold
human
medic
intervent
thu
bring
lasv
vaccin
analog
potenti
vaccin
emerg
diseas
clinic
may
difficult
nontechn
reason
although
renew
interest
multipl
intern
agenc
develop
human
vaccin
certain
emerg
pathogen
prudent
consid
approach
control
emerg
diseas
includ
feasibl
control
infect
sourc
pattern
diseas
emerg
viral
pathogen
human
wildlif
reservoir
clear
present
threat
continu
make
task
identifi
control
prevent
zoonos
difficult
daunt
goal
particularli
new
emerg
pathogen
may
complet
unknown
surveil
essenti
compon
success
control
programm
effect
contain
emerg
pathogen
epizoot
opportun
spill
human
popul
achiev
effect
largescal
cull
mass
vaccin
anim
nevertheless
abil
contain
even
known
emerg
virus
ebola
viru
wildlif
current
possibl
furthermor
manag
diseas
involv
livestock
rvf
cchf
pose
problem
convent
vaccin
suit
use
environ
major
limit
convent
vaccin
requir
individu
inocul
anim
costli
impract
strategi
targetreservoir
speci
anim
frequent
involv
emerg
highrisk
pathogen
surveil
work
focus
epizoot
may
becom
human
pathogen
use
goal
current
howev
predict
anim
pathogen
becom
establish
global
signific
emerg
human
diseas
guesswork
nevertheless
earli
stage
new
zoonosi
pathogen
virus
often
poorli
adapt
new
human
host
term
sustain
humantohuman
transmiss
lagphas
earli
zoonosi
may
therefor
provid
window
opportun
control
unrel
zoonot
pressur
emerg
pathogen
adapt
human
vaccin
target
pathogen
within
anim
transmiss
speci
could
therefor
bring
use
advantag
selfdissemin
vaccin
aim
immunolog
contain
emerg
virus
within
nonhuman
reservoir
host
offer
altern
convent
vaccin
approach
design
exploit
abil
replic
virusbas
vector
spread
anim
host
popul
avoid
need
direct
inocul
everi
anim
way
vaccin
limit
number
initi
anim
use
introduct
vaccin
target
popul
vaccin
engin
express
target
antigen
emerg
pathogen
interest
transmiss
vaccin
nonvaccin
anim
result
coordin
spread
specif
immun
emerg
pathogen
throughout
target
anim
popul
follow
earli
work
underpin
proof
principl
dissemin
vaccin
anim
pathogen
studi
target
human
pathogen
sin
nombr
orthohantaviru
snv
rodent
reservoir
deer
mous
peromyscu
maniculatu
prove
effect
approach
use
engin
cytomegaloviru
cmv
vector
caus
benign
transmiss
infect
host
express
snv
envelop
glycoprotein
similar
approach
also
develop
interrupt
zoonot
transmiss
ebola
viru
case
dissemin
cmv
vaccin
specif
great
ape
express
ebov
antigen
studi
african
ape
popul
wild
interestingli
one
goal
work
protect
great
ape
ebola
viru
diseas
major
threat
surviv
anim
wild
also
vaccin
emerg
pathogen
research
clinic
part
approxim
human
ebola
viru
outbreak
known
result
direct
handl
infect
ape
carcass
dissemin
cmvbase
strategi
may
signific
protect
human
clearli
work
need
conduct
assess
risk
live
transmiss
vaccin
evolv
pathogen
increas
virul
engin
wildlif
reservoir
vaccin
weakli
transmit
reproduct
number
r
make
transmiss
chain
short
maintain
might
way
address
justifi
safeti
risk
inde
mathemat
model
recent
demonstr
valu
approach
emerg
pathogen
repres
one
greatest
risk
global
health
alreadi
good
evid
zoonot
pathogen
probabl
transmit
key
anim
speci
resourcepoor
area
world
base
recent
histori
probabl
pathogen
never
seen
global
impact
west
african
outbreak
ebola
viru
underlin
stark
differ
healthcar
infrastructur
impact
upon
humantohuman
transmiss
emerg
pathogen
basic
healthcar
infrastructur
countri
rais
level
enabl
earli
identif
control
highrisk
pathogen
sourc
continu
respond
outbreak
emerg
diseas
long
epizoot
spill
human
popul
innov
strategi
therefor
urgent
requir
control
pathogen
vaccin
proven
approach
mani
novel
vaccin
strategi
develop
recent
year
potenti
specif
address
grow
threat
new
emerg
diseas
use
welldefin
vaccin
vector
platform
extens
record
safeti
efficaci
similar
pathogen
expedit
process
develop
valid
product
tabl
accordingli
design
licensur
particular
platform
vaccin
technolog
help
acceler
develop
new
vaccin
simpl
substitut
new
antigen
gene
vector
platform
requir
allow
manufactur
move
new
target
diseas
minim
chang
chemistri
manufactur
control
thu
new
vaccin
develop
focu
safeti
efficaci
insert
gene
addit
abil
platform
target
multipl
pathogen
help
justifi
invest
requir
build
maintain
manufactur
infrastructur
special
one
platform
singl
manufactur
facil
readi
produc
multipl
vaccin
time
addit
research
develop
selfdissemin
vaccin
control
potenti
pathogen
wildlif
reservoir
encourag
howev
progress
new
vaccin
necessari
regulatori
pathway
bring
clinic
requir
longterm
invest
govern
intern
organ
